Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was down 5.7% on Thursday following a weaker than expected earnings announcement. The stock traded as low as $74.14 and last traded at $75.94, with a volume of 2,078,591 shares changing hands. The stock had previously closed at $80.52.

The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.12. The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. The company’s quarterly revenue was up 82.9% on a year-over-year basis. During the same period last year, the business earned ($1.05) EPS.

A number of research firms have recently weighed in on ALNY. Cowen and Company restated a “buy” rating and set a $100.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, July 11th. Vetr downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 price target on the stock. in a report on Monday, May 15th. Piper Jaffray Companies set a $118.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Monday, May 15th. Barclays PLC raised their price target on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday. Finally, Credit Suisse Group raised their price target on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the company an “outperform” rating in a report on Tuesday, June 27th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $81.74.

In related news, SVP Akshay Vaishnaw sold 43,750 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, May 15th. The shares were sold at an average price of $65.00, for a total value of $2,843,750.00. Following the transaction, the senior vice president now owns 43,047 shares in the company, valued at approximately $2,798,055. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Laurie Keating bought 11,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 30th. The stock was purchased at an average price of $65.35 per share, for a total transaction of $751,525.00. Following the acquisition, the senior vice president now directly owns 11,500 shares in the company, valued at $751,525. The disclosure for this purchase can be found here. Insiders sold a total of 64,125 shares of company stock worth $4,325,000 in the last quarter. Insiders own 4.30% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares during the period. Perceptive Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 831.4% in the first quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock valued at $56,553,000 after buying an additional 985,000 shares during the period. Rockefeller Financial Services Inc. increased its position in shares of Alnylam Pharmaceuticals by 4,724.4% in the first quarter. Rockefeller Financial Services Inc. now owns 506,223 shares of the biopharmaceutical company’s stock valued at $25,944,000 after buying an additional 495,730 shares during the period. TIAA CREF Investment Management LLC increased its position in shares of Alnylam Pharmaceuticals by 305.0% in the second quarter. TIAA CREF Investment Management LLC now owns 508,852 shares of the biopharmaceutical company’s stock valued at $40,586,000 after buying an additional 383,214 shares during the period. Finally, Blue Ridge Capital L.L.C. increased its position in shares of Alnylam Pharmaceuticals by 20.5% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,590,000 shares of the biopharmaceutical company’s stock valued at $81,488,000 after buying an additional 270,000 shares during the period. Hedge funds and other institutional investors own 88.96% of the company’s stock.

The stock’s market cap is $6.55 billion. The company has a 50-day moving average of $81.35 and a 200 day moving average of $61.53.

TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price Down 5.7% on Disappointing Earnings” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/alnylam-pharmaceuticals-inc-alny-stock-price-down-5-7-on-disappointing-earnings/1469738.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.